The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week found that so far relatively few people with HIV are taking ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

A CRISPR-based gene-editing therapy called EBT-101 was safe and well tolerated but did not prevent viral rebound in three participants who stopped antiretroviral treatment in an early study, according ...

A once-weekly oral regimen can keep HIV suppressed as well as daily pills, according to study results presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).

The DoxyPEP trial enrolled more than 500 gay and bisexual men and transgender women in San Francisco and Seattle who were either living with HIV or taking PrEP. In 2022, Professor Annie Luetkemeyer of ...

The British HIV Association (BHIVA) has recommended that everyone living with HIV aged 40 and over should take a statin to reduce their risk of heart disease, even if they do not have raised ...

Budigalimab, a monoclonal antibody that blocks the PD-1 receptor on immune cells, was associated with delayed HIV rebound or sustained low viral load in a majority of people who interrupted ...

In some cases, HIV can bypass the barrier that encases the brain and cerebrospinal fluid which can contribute to brain inflammation and neurocognitive symptoms. However, diagnosing this viral ‘escape’ ...

People who used lenacapavir (Sunlenca) pills when injections were temporarily unavailable maintained viral suppression with no safety concerns, according to study results presented this week at ...